AbCellera Biologics Inc. (ABCL)
收市後：
AbCellera Biologics Inc.
2215 Yukon Street
Vancouver, BC V5Y 0A1
Canada
604-559-9005
https://www.abcellera.com
版塊: Healthcare
行業: Biotechnology
全職員工: 586
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Dr. Carl L.G. Hansen Ph.D. | CEO, President & Chairperson | 711.47k | 1.85M | 1975 |
| Mr. Andrew Booth M.B.A. | Chief Financial Officer | 642.42k | 510.82k | 1974 |
| Dr. Veronique Lecault Ph.D. | COO & Director | 645.07k | 無 | 1985 |
| Mr. Tryn T. Stimart Esq., J.D., M.Sc. | Chief Legal Officer, CCO, Compliance Officer, Corporate Secretary & Privacy Officer | 644.4k | 無 | 1970 |
| Mr. Neil Aubuchon B.A., M.B.A. | Chief Commercial Officer | 684.81k | 無 | 1971 |
| Marcie Thiessen CPA, CGA | Senior Director of Finance & Accounting | 無 | 無 | 無 |
| Dr. Ester Falconer Ph.D. | Chief Technology Officer | 無 | 無 | 1975 |
| Kathleen Reid B.A. | Head of Corporate Communications | 無 | 無 | 無 |
| Graham Craig M.Sc. | Director of Corporate Development | 無 | 無 | 無 |
| Mr. Murray McCutcheon Ph.D. | Senior Vice President of Partnering | 無 | 無 | 無 |
描述
AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
公司管治
截至 2024年5月1日 止，AbCellera Biologics Inc. 的 ISS 管治質素評分為 9。 Pillar 分數正在審核中：9；董事會：10；股東權利：4；現金賠償：9。
